SOURCE: Ablynx

October 26, 2010 01:37 ET


GHENT, BELGIUM--(Marketwire - October 26, 2010) - Ablynx [Euronext Brussels: ABLX] will showcase its clinical and pre-clinical portfolio during its R&D Day, to be held today at its new facilities in Ghent, Belgium. Ablynx has built an impressive range of Nanobody-based therapeutic programmes, seven of which could reach the clinical proof-of-concept stage over the next three years.

R&D Day Highlights

· Progress with the clinical portfolio

Ablynx will provide an update on all its clinical programmes including its anti-von Willebrand Factor programmes (ALX-0081/ALX-0681) for the orphan disease indication thrombotic thrombocytopenic purpura (TTP) which recently entered a Phase II study and its on-going Phase II study in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) where due to some further delays in patient recruitment the Company now expects to report clinical proof-of-concept data in the second half of 2011. Ablynx's third clinical programme, an anti-RANKL Nanobody (ALX-0141) currently in Phase I in post-menopausal women, is still on track to report final data during the first half of 2011. Ablynx will also provide an overview of the status of ATN- 103, the anti-TNF-alpha Nanobody currently in Phase II clinical trials with its partner Pfizer, which is still expected to generate proof-of-concept data in the first half of 2011.

· Next into the clinic

Progress in three pre-clinical programmes, which are expected to enter clinical trials during 2011, will also be detailed. Ablynx is on track to file an IMPD for ALX-0061 (anti-IL-6R) before the end of 2010 with the goal of entering into a Phase I/II study in rheumatoid arthritis patients during the first quarter of 2011. The clinical plans for ALX-0651 (anti-CXCR4) for stem cell mobilization and ALX-0171 (anti-RSV), which is the first Nanobody programme to be administered via pulmonary delivery, will also be presented.

· Corporate and business update

Ablynx will also provide a corporate and business update on the Company's progress and strategy going forward.

Ablynx's CEO and Chairman Dr Edwin Moses commented: "We are extremely pleased with the rapid progress of our pipeline over the last year. ..


Complete version of the press release:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

Contact Information

  • For more information, please contact Ablynx:

    Dr. Edwin Moses
    Chairman and CEO
    t: +32 (0)9 262 00 07
    m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
    e: Email Contact

    Eva-Lotta Allan
    Chief Business Officer
    t: +32 (0)9 262 00 75
    m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
    e: Email Contact